A federal jury in Delaware put US biotech major Amgen (Nasdaq: AMGN) on the hook Thursday for at least $271.2 million in ...

Regeneron’s lead counsel was Jonathan D. Polkes of White & Case LLP.

Key products like Prolia and Repatha saw strong sales growth, though Enbrel and Tepezza experienced declines. Amgen reaffirmed its full-year guidance and continues to focus on expanding its ...

Experts in HoFH are calling for NHS England to make Amgen's Repatha (evolocumab) and Aegerion's Lojuxta (lomitapide) available. Aegerion and specialist doctors are calling on NHS England to ...

CNS disorders rake in more than $ 80 billion a year for the pharma industry, however higher failure rates in clinical trials are forcing big companies to cut down their spend on CNS drug R&D ...

Notable contributors included Repatha (evolocumab) for hypercholesterolemia and hyperlipidemia, Blincyto (blinatumomab) for B-cell acute lymphocytic leukaemia, recently approved in June 2024, and ...

Notable contributors included Repatha (evolocumab) for hypercholesterolemia and hyperlipidemia, Blincyto (blinatumomab) for B-cell acute lymphocytic leukaemia, recently approved in June 2024 ...

Background: There is sparse high-quality safety and effectiveness data for pulsed field ablation (PFA) of persistent atrial fibrillation (PerAF), where lesions beyond pulmonary vein isolation (PVI) ...

We recently published a list of the 11 Cheap NASDAQ Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other ...

Amgen’s General Medicine segment is led by Repatha and EVENITY. Repatha reduces the risks of myocardial infarction, stroke, and coronary revascularization. Whereas EVENITY is used for the ...